ClinicalTrials.gg
RecruitingNCT05853419CHANGEUpdated Aug 20, 2025

Change History and Adopt a Robotic SolutioN for anGioplasty procedurE

An observational study in Coronary Disease, sponsored by Robocath. Recruiting at 8 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Robocath · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Coronary Disease with a site in France — 3 open to participants now, 5 under way, none of them phase 3. Coronary Disease · France.

Planned enrollment
5th of 15
500 · median 294
Started
2023
the only one that year
Observational
15 of 58
2 open now
Registered
53rd of 58
by date

Among the 58 studies in Coronary Disease with a site in France, this one is the 5th largest by planned enrollment of the 15 observational ones that give a count, is the only one that started in 2023, is one of 15 observational ones, and was the 53rd registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

3 of the 58 studies in Coronary Disease with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Coronary Disease with a site in France, or all of them as a file.
02

Study summary

The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.

Read the detailed description

The R-One system is a class "IIb" CE marked medical device designed to remote deliver and manipulate coronary guidewires and stent/balloon devices during Percutaneous Coronary Intervention (PCI). The system comprises the R-One Robotic Platform used in combination with two accessories, the Mobile Radioprotection Screen and a sterile and single-use R-One Consumable Kit. The R-One is not autonomous and operates only under the operator's commands.

This study is a single-arm, open-label, multi-center registry.

The CHANGE registry, part of the ROBOCATH's post-market clinical follow-up activities, is a real world study aiming to confirm the safety and performance, including the clinical benefit, of the R-One robotic systems medical device.

500 patients with coronary artery disease and with clinical indication for PCI will be recruited in up to Up to 15 centers distributed in Europe and South Africa.

03

Conditions studied

  • Coronary Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with coronary artery disease and a clinical indication for PCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age ≥ 18 years;
  • 2.Subjects with coronary artery disease with clinical indication for PCI;
  • 3.Subject deemed appropriate for robotic-assisted PCI; and
  • 4.The subject has been informed of the nature of the study, agrees to its provisions and has provided written .

Exclusion criteria

Exclusion Criteria:

  • 1.Failure/inability/unwillingness to provide , unless the ethic committee has waived informed consent; or
  • 2.The Investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted PCI.
  • 3.STEMI
  • 4.Cardiogenic shock
  • 5.Subjects will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Study population

    Adult patients with coronary artery disease and a clinical indication for PCI

    Device: Robotic-assisted PCI

Interventions

  • DeviceRobotic-assisted PCI

    Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer

06

What researchers measure

Primary outcomes

  1. Clinical success

    Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the R-One System, without in-hospital major adverse cardiac events (MACE).

    Time frame: From Day 0 to Day 3

  2. Technical success

    Absence of any unplanned manual assistance or conversion to manual PCI for procedural completion

    Time frame: During procedure

Secondary outcomes

  1. Radiation exposure for the patient

    Dose (DSP and Air Kerma) measured by the imaging system during the procedure.

    Time frame: During procedure

  2. Overall Procedure Time

    Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.

    Time frame: During procedure

  3. Overall contrast volume

    Total volume of contrast (mL) used during the procedure.

    Time frame: During procedure

  4. Radiation exposure for the operator

    Cumulative dose the operator receives as recorded from an electronic pocket dosimeter during the procedure.

    Time frame: During procedure

  5. Fluoroscopy Time

    Total fluoroscopy utilized during the procedure as recorded by an Imaging System.

    Time frame: During procedure

  6. Safety event occurrence

    Medical device's safety event occurrence

    Time frame: From Day 0 to Day 3

07

Study locations

5 of 8 sites recruiting
  • Het Ziekenhuisnetwerk Antwerpen vzw
    Antwerp, 2000, Belgium
    Recruiting
    • Stefan Verheye, Prof.MD · Contact
    • Stefan Verheye, Prof.MD · Principal investigator
  • Brest university hospital
    Brest, Brittany Region 29609, France
    Recruiting
    • Romain Didier, Prof. MD · Contact
    • Romain DIDIER, Prof.MD · Principal investigator
  • Rouen university hospital
    Rouen, 76000, France
    Recruiting
    • Eric Durand, Prof.MD · Contact
    • Eric Durand, Prof.MD · Principal investigator
  • Centre Cardiologique du Nord
    Saint-Denis, Île-de-France Region 93200, France
    Recruiting
    • Mohamed Nejjari, MD · Contact
    • Mohammed NEJJARI, MD · Principal investigator
    • Franck Digne, MD · Sub investigator
  • Rheinland Klinikum Neuss GmbH
    Neuss, Lukaskrankenhaus 41464, Germany
    Recruiting
    • Michael Haude, Prof.MD · Contact
    • Michael HAUDE, Prof.MD · Principal investigator
  • San Donato Policlinco Kardia
    San Donato Milanese, MI 20097, Italy
    Not yet recruiting
    • Francesco BEDOGNI · Contact
    • Francesco BEDOGNI, MD · Principal investigator
  • Polskie Towarzystwo Kardiologiczne
    Warsaw, Par Défaut 02-507, Poland
    Not yet recruiting
    • Robert J Gil · Contact
    • Robert J GIL, Prof.MD · Principal investigator
  • Netcare Christiaan Barnard Memorial Hospital
    Cape Town, le Cap 8001, South Africa
    Not yet recruiting
    • Faizel Lorgat, MD · Contact
    • Faizel LORGAT, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for May 2026, 35 months after the start.

Of 154 observational studies under Coronary Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 123. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
May 10, 2023
StartActual
Jun 20, 2023
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05853419
Lead sponsor
Robocath
Collaborators
European Cardiovascular Research Center
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Jun 20, 2023
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 20, 2025

Study contacts

Hamouda Abassi, PhD
Contact
hamouda.abassi@robocath.com
+33 2 32 10 67 42
Stefan Verheye, Prof.MD
principal investigator · Het Ziekenhuisnetwerk Antwerpen vzw
Michael Haude, Prof.MD
principal investigator · Rheinland Klinikum Neuss GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion